With the fast moving, ever-changing landscape of healthcare today, the mission of AJMC TV is to inform payers, clinical decision makers, and policy makers through brief video interviews providing the most recent and important information.
Lee Newcomer, MD, MHA, Describes NCCN’s Approach to Genetic Testing
Lee Newcomer, MD, MHA, of Oncology, Genetics and Women's Health for UnitedHealthcare, says the National Comprehensive Cancer Network is transforming genetic testing by utilizing a tool called the NCCN Biomarkers Compendium, which encourages evidence-based decision-making.
Edmund J. Pezalla, MD, MPH, Describes Aetna’s Approach to Managing Obesity
Edmund J. Pezalla, MD, MPH, national medical director, Aetna Pharmacy Management, says that Aetna recognizes the implications of the obesity epidemic and how it contributes to a variety of other medical problems such as diabetes and hypertension.
Christine Strahl, PharmD, MBA, BCPS, Discusses Channels and Methods for Specialty Pharmacy Distribution
Christine Strahl, PharmD, MBA, BCPS, specialty pharmacy program manager, HealthPartners, says there are several new distribution channels in specialty pharmacy.
Episode 11 – Personalized Medicine in CRPC
During this segment, the panelists review the use of personalized medicine in castration-resistant prostate cancer.
April 2014
Current Issue | Archives

April 2014

Volume: 20
Number: 4
Bruce Feinberg, DO; Scott Milligan, PhD; Tim Olson, MBA; Winston Wong, PharmD; Daniel Winn, MD; Ram Trehan, MD; and Jeffrey Scott, MD
Sabina Ohri Gandhi, PhD; and Lindsay Sabik, PhD

March/April 2014
Current Issue | Archives

March/April 2014

Volume: 6
Number: 2
Sara C. Erickson, PharmD; Wenyi Qiu, MS; Crystal R. Maas-Patel, PharmD; Sharon M. Wang, PharmD, MS; and Bimal V. Patel, PharmD, MS
Catherine I. Starner, PharmD, BCPS; R. Scott McClelland, PharmD; Yang Qiu, MS; Richard A. Zabinski, PharmD; Nancy Cotter, PharmD; and Patrick P. Gleason, PharmD, BCPS, FCCP

Wednesday, April 23rd, 2014
HCV Drug Sets Record Sales
Katie Sullivan, MA
Initial sales of Sovaldi (sofosbuvir), Gilead’s new drug for the treatment of hepatitis C virus infection (HCV), set a sales record in its first quarter on the market in the United States. In fact, Sovalidi outpaced the sales of any other drug in its class, netting $2.1 billion in revenue—or approximately $25 million per day.

Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.
Previous TabNext Tab